Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology

Drug Safety

Volumn 27, Issue 7, 2004, Pages 427-456

  Clark, David W J ^a,d   Layton, Deborah ^b,c   Shakir, Saad A W ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; VALDECOXIB; WARFARIN;

ALZHEIMER DISEASE; ARTERY THROMBOSIS; BACKACHE; BLOOD TOXICITY; BLOOD VESSEL INJURY; BONE DISEASE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM INJURY; DISABILITY; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; EAR DISEASE; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; EYE DISEASE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEPATOBILIARY DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LUNG EMBOLISM; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; PERIPHERAL VASCULAR DISEASE; PHARMACOEPIDEMIOLOGY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZATION; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; REVIEW; RISK; SIDE EFFECT; SKIN DISEASE; SODIUM RETENTION; STOMACH DISEASE; STROKE; SUDDEN DEATH; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ULCER; UNSTABLE ANGINA PECTORIS; VASCULAR INFLAMMATION; VEIN THROMBOSIS;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES; SULFONES; THROMBOEMBOLISM;

EID: 2942577838     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427070-00002     Document Type: Review

References (98)

1. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19 (6 Suppl. 25): S31-6
2. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105 (14): 1620-2
3. Food and Drug Administration Advisory Committee. Cardiovascular safety review of rofecoxib [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/ 3677b2_06_cardio.pdf [Accessed 2001 Sep 8]
4. Vane J. Towards a better aspirin. Nature 1994; 367 (6460): 215-6
5. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90 (24): 11693-7
6. Vinals M, Martinez-Gonzalez J, Badimon JJ, et al. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (COX-2). Arterioscler Thromb Vasc Biol 1997; 17(12): 3481-8
7. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999; 274 (17): 11660-6
8. FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001; 107(11): 1335-7
9. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on cyclooxygenase-2 (COX-2) versus cyclooxygenase-1 (COX-1) in healthy volunteers. J Clin Pharmacol 2000; 40 (10): 1109-20
10. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40 (2): 124-32
11. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96 (1): 272-7
12. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167 (5): 2831-8
13. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102 (8): 840-5
14. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104 (7): 820-5
15. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296 (5567): 539-41
16. Sperling R, Braunstein N, Melin J, et al. Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford, et al. Arthritis Rheum 2001; 44 (5): 1229-30
17. Verma S, Raj SR, Shewchuk L, et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001; 104 (24): 2879-82
18. Tuleja E, Mejza F, Cmiel A, et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Thromb Vasc Biol 2003; 23 (6): 1111-5
19. Linder JD, Monkemuller KE, Davis JV, et al. Cyclooxygenase-2 (COX-2) inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000; 93 (9): 930-2
20. Crofford LJ, Dates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 (COX-2) inhibitors: a report of four cases. Arthritis Rheum 2000; 43 (8): 1891-6
21. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107 (3): 405-9
22. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 (COX-2) is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19 (3): 646-55
23. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105 (14): 1650-5
24. Title LM, Giddens K, McInerney MM, et al. Effect of cyclooxygenase-2 (COX-2) inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003; 42 (10): 1747-53
25. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69 (1): 180-6
26. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433-42
27. Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56 (2): 167-74
28. Blain H, Boileau C, Lapicque F, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of non-steroidal anti-inflammatory drugs (NSAIDs) in clinical use. Br J Clin Pharmacol 2002; 53 (3): 255-65
29. Fujii K, Konishi K, Kanno Y, et al. Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment. J Dermatol 2001; 28 (5): 248-50
30. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor: pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290 (2): 551-60
31. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65 (3): 336-47
32. Range SP, Pang L, Holland E, et al. Selectivity of cyclooxygenase inhibitors in human pulmonary epithelial and smooth muscle cells. Eur Respir J 2000; 15 (4): 751-6
33. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296 (2): 558-66
34. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002; 89 (6A): 3D-9D
35. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120 (3): 594-606
36. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287 (1): 64-71
37. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48 (11): 3102-11
38. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 (COX-2) inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 (COX-1) inactivation by aspirin. Proc Natl Acad Sci U S A 2001; 98 (25): 14583-8
39. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25): 1809-17
40. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor (COX-2), rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40 (12 Pt 2): 1509-15
41. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002; 42 (9): 1027-30
42. Verma S, Szmitko PE. Coxibs and the endothelium. J Am Coll Cardiol 2003; 42 (10): 1754-6
43. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126 (8): 638-44
44. Sackett DL, Straus ES, Richardson WS, et al. Guidelines. Table 7.2. Levels of evidence and grades of recommendations. Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingstone, 2000: 173-7
45. Mann RD. Prescription-event monitoring: recent progress and future horizons. Br J Clin Pharmacol 1998; 46 (3): 195-201
46. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-8
47. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308 (6921): 81-106
48. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308 (6923): 235-46
49. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993; 14 (7): 951-7
50. Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis. Drugs Aging 2001; 18 (5): 369-88
51. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104 (19): 2280-8
52. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11 (4): 382-7
53. Garcia Rodriguez LA. The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin Exp Rheumatol 2001; 19 (6 Suppl. 25): S41-4
54. Bannwarth B, Treves R, Euller-Ziegler L, et al. Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. Drug Saf 2003; 26 (1): 49-54
55. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 89 (2): 204-9
56. Weir MR, Sperling RS, Reicin A, et al. Selective cyclooxygenase-2 (COX-2) inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146 (4): 591-604
57. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000; 284 (10): 1247-55
58. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89 (4): 425-30
59. White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92 (4): 411-8
60. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective cyclo-oxygenase-2 (COX-2) inhibitors. JAMA 2001; 286 (8): 954-9
61. GD Searle & Co. CLASS Advisory Committee Briefing Document [online]. Available from URL: http://www.fda.gov/ ohrms/dockets/ac/01/briefing/ 3677b1_01_searle.pdf [Accessed 2001 Sep 8]
62. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324 (7349): 1287-8
63. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001; 286 (19): 2398-400
64. Geis GS. Are selective COX 2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs (NSAIDs)? Pharmacia's response to editorial. BMJ 2002; 325 (7356): 161
65. Reicin AS, Black G, Chen I, Cardiovascular safety profile of rofecoxib in elderly patients with Alzheimer's disease or cognitive impairment; a pooled analysis [abstract]. Ann Rheum Dis 2002; 61 (1 Suppl. 1): 33-4
66. Konstam MA. Matters of the heart: assessing the cardiovascular safety of new drugs. Am Heart J 2003; 146 (4): 561-2
67. Mukherjee D, Topol EJ. Pharmaceutical advertising versus research spending: are profits more important than patients? Am Heart J 2003; 146(4): 563-4
68. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162 (10): 1111-5
69. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162 (10): 1099-104
70. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162 (10): 1105-10
71. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal antiinflammatory drugs. Circulation 2003; 108 (10): 1191-5
72. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47 (4): 349-55
73. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30 (1): 36-40
74. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30 (6): 1196-202
75. Matheson AJ, Figgitt DP. Rofecoxib; a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001; 61 (6): 833-65
76. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359 (9301): 118-23
77. Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002; 18(4): 229-36
78. Layton D, Riley J, Wilton LW, et al. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2002; 55: 166-74
79. Layton D, Wilton LW, Shakir SA. Celecoxib. PEM report No. 74. Oct 28, 2002
80. Ray W, Stein C, Daugherty J, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360 (9339): 1071-3
81. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163 (4): 481-6
82. Layton D, Heeley E, Hughes K, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42 (11): 1342-53
83. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50 (1): 35-42
84. Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42 (11): 1354-65
85. The relationship between selective cyclo-oxygenase-2 (COX-2) inhibitors and acute myocardial infarction [abstract 1823] [online]. American College of Rheumatology 2003 Scientific Meeting; 2003 Oct 23-28; 2003. Available from URL: http:// www.rheumatology.org/educ/sessions/index.asp?aud=mem [Accessed 2004 Jan 28]
86. Shakir SA. PEM in the UK. In: Mann RD, Andrews E, editors. Pharmacovigilance. Chichester, UK: John Wiley & Sons, 2002: 333-44
87. Strom B. Study designs available for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons Ltd, 2000: 17-29
88. Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93-4
89. Waller P, Lee E. Responding to drug safety issues. Pharmacoepidemiol Drug Saf 1999; 8: 535-52
90. Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23 (6): 533-42
91. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23 (9): 1478-91
92. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26 (3): 159-86
93. Vu D, Murty M, McMorran M. Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse reactions. Can Adv Reaction News 2002; 12 (2): 1-3
94. Coulter DM. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach. Drug Saf 2002; 25 (6): 433-9
95. Coulter D. COX-2 use in New Zealand: a problem of age and death [abstract]. Proc Aust Soc Clin Exp Pharmacol Toxicol 2003; 10: 110
96. Clarke A, Shakir SAW. Evidence of safety used to support decisions to withdraw medicinal products from the UK and US markets: a literature review. Pharmacoepidemiol Drug Saf 2003; 12 Suppl. 1: S149-50
97. Gimeno V, Castellsague J, Varas C, et al. Gastrointestinal and cardiovascular characterization of users of cyclo-oxygenase-2 (COX-2)-specific inhibitors. Ist International Conference on Therapeutic Risk Management and 19th International Conference on Pharmacoepidemiology; 2003 Aug 21-24; Philadelphia (PA). Pharmacoepidemiol Drug Saf 2003; 12 Suppl. 1: S43
98. Howes L, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25 (12): 829-35